Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells

(2016) Meromit Singer et al.   CELL

Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages

(2016) Lifeng Li et al.   INTERNATIONAL JOURNAL OF CANCER

TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

(2016) B. V. Park et al.   Cancer Discovery

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance

(2016) Marije Baas et al.   eLife

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

(2015) Mario E. Lacouture et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Activated NKT Cells Can Condition Different Splenic Dendritic Cell Subsets To Respond More Effectively to TLR Engagement and Enhance Cross-Priming

(2015) Taryn L. Osmond et al.   JOURNAL OF IMMUNOLOGY

TGF-β3-expressing CD4+CD25−LAG3+ regulatory T cells control humoral immune responses

(2015) Tomohisa Okamura et al.   Nature Communications

PD-1 induction through TCR activation is partially regulated by endogenous TGF-β

(2014) Raja Rekik et al.   Cellular & Molecular Immunology

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

(2014) ALLEN COHN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

(2014) John C. Morris et al.   PLoS One

Induction and molecular signature of pathogenic TH17 cells

(2012) Youjin Lee et al.   NATURE IMMUNOLOGY

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

Systemic Inhibition of Transforming Growth Factor-  in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines

(2009) R. Ueda et al.   CLINICAL CANCER RESEARCH

Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-  Monoclonal Antibody

(2009) M. Terabe et al.   CLINICAL CANCER RESEARCH

TGF-β3 and cancer: A review

(2009) H.G. Laverty et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Blockade of TGF-β enhances tumor vaccine efficacy mediated by CD8+T cells

(2009) Shun Takaku et al.   INTERNATIONAL JOURNAL OF CANCER

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

Systemic Blockade of Transforming Growth Factor-  Signaling Augments the Efficacy of Immunogene Therapy

(2008) S. Kim et al.   CANCER RESEARCH

Tumor-Induced Immune Suppression of In vivo Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor  

(2008) S. Wei et al.   CANCER RESEARCH

TGF-β: A Master of All T Cell Trades

(2008) Ming O. Li et al.   CELL